Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine

The presence of FLT3-ITD mutation is associated with relapse and poor survival in AML patients. Venetoclax combined with hypomethylating agents (VEN+HMA) was approved for the frontline treatment of elderly or unfit AML patients, which leads to noteworthy impacts on AML management. The combination th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lei-Si, Wang, Jun, Xu, Ming-Zhu, Wu, Tian-Mei, Huang, Si-Man, Cao, Han-Yu, Sun, Ai-Ning, Liu, Song-Bai, Xue, Sheng-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865758/
https://www.ncbi.nlm.nih.gov/pubmed/35221695
http://dx.doi.org/10.2147/OTT.S336715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865758/
https://www.ncbi.nlm.nih.gov/pubmed/35221695
http://dx.doi.org/10.2147/OTT.S336715

Ejemplares similares